Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...

Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...